Rectify Pharma

Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein function and address the underlying cause of serious diseases.

[Rectify Pharma @RectifyPharma]

Today, we announced selection of our lead small molecule #PFM for treatment of hepatobiliary diseases by improving bile composition and enhancing bile flow. We look forward to advancing to first-in-human clinical trials for primary sclerosing cholangitis. https://t.co/2Tg2fOUMRJ

[Rectify Pharma @RectifyPharma]

At #EASLCongress 2026 we are presenting new translational data with our clinical candidate RTY-406 that further supports its potential as a first-in-class disease-modifying treatment for PSC and other hepatobiliary diseases.

Learn more: https://t.co/QQzu78pohY

[Rectify Pharma @RectifyPharma]

Heading to #EASLCongress 2026? We look forward to connecting with the global liver community & sharing new preclinical data on RTY-406, our dual ABCB4/BSEP #PFMs candidate in development for #PSC & other hepatobiliary diseases. Learn more: https://t.co/NHk3kepPVV

[Rectify Pharma @RectifyPharma]

Our new publication in Liver International Communications demonstrates how partial loss of ABCB4 function causes toxic bile composition and drives inflammation, fibrosis and liver injury. Read more: https://t.co/WBD0sDXGeX

[Rectify Pharma @RectifyPharma]

Protein dysfunction frequently underlies the development of serious diseases. At Rectify, we are advancing precision approaches to restore protein function and address underlying drivers of disease.​

Learn more: https://t.co/9OQsL11JQh

[Rectify Pharma @RectifyPharma]

#PrimarySclerosingCholangitis brings daily uncertainty and complex challenges for patients and caregivers. Supporting and advocating for this community is essential. Learn more about our work in #PSC: https://t.co/9OQsL11JQh

[Rectify Pharma @RectifyPharma]

Our CEO, @r_devraj, will join the “Pipeline Prioritization” panel at @LongwoodLeaders #MiamiCEO, convening leaders across the biotech, pharma, academia, regulatory & investment communities to discuss key issues shaping life sciences.​

Learn more: https://t.co/Sq7X77SAgq

[Rectify Pharma @RectifyPharma]

In support of #RareDiseaseDay, we stand with the millions affected by rare diseases worldwide. At Rectify, this fuels our commitment to advance science for rare hepatobiliary diseases. Learn more: https://t.co/a9vSmDN3IS

[Rectify Pharma @RectifyPharma]

Rare hepatobiliary diseases often mean delayed diagnosis, limited options, and daily symptoms that affect quality of life. At Rectify, we are developing #PFMs to restore protein function and address hepatobiliary diseases like #PSC. Learn more: https://t.co/9OQsL11JQh

[Rectify Pharma @RectifyPharma]

Our CEO @r_devraj joined The BioHub Podcast to discuss Rectify’s vision for advancing a new class of oral small molecules: our #PFMs. Here, Raj shares how we’re prioritizing unmet medical needs in diseases like #PSC.

Tune in here: https://t.co/q53Z5Hltut

[Rectify Pharma @RectifyPharma]

Today our CEO @r_devraj shared his perspective on the 2026 healthcare & biotech venture outlook in @WSJ ProVenture newsletter, pointing to renewed market confidence, greater focus on de-risked assets, reopening of M&A & IPOs, and regulatory uncertainty as a key challenge.

[Rectify Pharma @RectifyPharma]

Over 50% of cholestatic chronic liver disease patients carry pathogenic variants in ABCB4 or BSEP, with ABCB4 heterozygosity, the most common genotypic burden seen in 74% of cases. Our dual ABCB4/BSEP PFM offers a targeted therapy for this growing, underserved patient population.

[Rajesh Devraj @r_devraj]

New research shows over 50% of adults with cholestatic chronic liver disease carry pathogenic variants in bile transporter genes, including ABCB4 and BSEP. This supports why @Rectify Pharma is advancing an oral, dual-targeted ABCB4/BSEP PFM. Read more: https://t.co/fAxye1LTGB

[Rectify Pharma @RectifyPharma]

A new year brings renewed focus on science that can change what’s possible for future patients. At Rectify, we remain committed to advancing disease-modifying therapies and translating discovery into real-world impact.

[Boehringer Ingelheim @Boehringer]

#NEWS: Chronic kidney disease impacts ~1 in 10 adults (~850 million people). Together with @RectifyPharma, we’re targeting underlying disease mechanisms linked to calcification and cardiorenal risk.

Learn more at https://t.co/gBrHNHLAkW

#ResearchCollaboration #CKD

[Rectify Pharma @RectifyPharma]

We’re pleased to partner with @Boehringer to advance new treatments for chronic kidney disease (#CKD) & other conditions. We will leverage our #PFM platform to develop oral therapies that enhance ABCC6 function to address cardiorenal dysfunction. Read: https://t.co/W4gw7ux4Rw

[Rectify Pharma @RectifyPharma]

How can restoring transporter function help rare liver diseases like PSC? Our CMO Dr. Pol Boudes, MD explains Rectify’s dual-modulator strategy and potential clinical plans on @XTalks.​

Listen here: https://t.co/G27zi5jecE

[Rectify Pharma @RectifyPharma]

Primary Sclerosing Cholangitis (PSC) causes bile duct scarring and blocked bile flow. Our #PositiveFunctionalModulators (PFMs) aim to restore bile transport, reduce inflammation, and slow disease even without a genetic cause.​

Learn more: https://t.co/bH8WhM4R4v

[Rectify Pharma @RectifyPharma]

#DYK? PBC was renamed from Primary Biliary Cirrhosis, since patients now get diagnosed before cirrhosis. Similarly, PSC patients are diagnosed before bile duct sclerosis. ​

Fact: PSC starts as inflammation from toxic bile harming bile duct cells. Should PSC get a new name too?

[Rectify Pharma @RectifyPharma]

From rare genetic disorders to more common conditions, hepatobiliary diseases highlight the complexity of liver health. This #LiverDiseaseAwarenessMonth, we remain focused on pioneering PFMs to restore function where it’s needed most.​

Learn more: https://t.co/6Jt6XJQSQc

[Rectify Pharma @RectifyPharma]

#PSC is a chronic liver disease causing bile duct inflammation and fibrosis. Our #PositiveFunctionalModulators (PFMs) enhances bile transporter function, improving bile flow and reducing inflammation. We aim to transform PSC treatment. Learn more: https://t.co/9OQsL11JQh

[Rectify Pharma @RectifyPharma]

By targeting the root causes of disease, we aim to deliver therapies that truly modify disease progression. Our #PositiveFunctionalModulators are oral small molecules designed to transform the function of membrane proteins. Learn more: https://t.co/6Jt6XJQSQc